DES (drug-eluting stent) patent ruling in favour of Boston prepares settlement with Johnson & Johnson
This article was originally published in Clinica
Executive Summary
The decision by a jury in the district court of Delaware on July 1 that Johnson & Johnson's Cypher stent infringes two patents owned by Boston Scientific could pave the way for a deal between the two companies, which to date are the only manufacturers to market drug-eluting stents (DESs) in the US.